SALT LAKE CITY, Sept. 6 /PRNewswire-FirstCall/ -- LipidViro Tech, Inc. (OTC Bulletin Board: LPVT - News) comments on Phase III data presented by competitor Vasogen Inc. at the 2006 World Congress of Cardiology, Sept 2-6 Barcelona, Spain. Vasogen and LipidViro Tech are developing competing apoptotic therapies for treating Chronic Heart Failure (CHF). New results from Vasogen’s landmark Phase III CHF study reported (1):
